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vein before the distal anastomoses were
performed. In case of uncertainty or bleed-
ing, the Symmetry connector was replaced.
Before closing the chest, we reassessed
flow with an additional measurement by
using the transit time flow probe (Medi-
Stim, Oslo, Norway).
No neurologic deficiencies were ob-
served, and 54 of 61 patients had an un-
eventful postoperative course. However, in
7 (11.5%) of 61 patients, we encountered
device-related complications: in 1 patient
occurring intraoperatively, in 2 patients
within 5 days after the operation, and in 4
patients within 6 months postoperatively.
Six patients were subjected to repeat
coronary angiography: 1 patient had ven-
tricular fibrillation and consequent resusci-
tation; 5 patients had a recurrence of an-
gina, dyspnea, or both; and 1 patient had
loss of flow detected intraoperatively with
a new image system (Spy Novadaq, To-
ronto, Ontario, Canada). This occlusion
was due to an aortic plaque that was not
properly cut by the Symmetry cutter and
therefore closed the new aortic opening
like a cover. Repeat angiography in 6 of 7
patients showed an occlusion of the vein
graft right at the neo-ostium. Kinking of
the graft was never observed as a possible
cause of closure. Three patients underwent
reoperation within 6 days. In 1 patient the
graft was dilated, in 2 patients the graft was
stented, and in 1 patient further treatment
was not considered necessary because of
the small size of anastomosed artery.
On the basis of these observations, we
have stopped the routine use of the Sym-
metry connector and reserve the device for
patients who have a severely calcified as-
cending aorta (grade IV-V), in whom other
alternative techniques (vein anastomosis to
the internal thoracic artery or to the innom-
inate artery) are not possible.
Although we fully acknowledge the po-
tential benefits of a nontouch vein graft–
aorta anastomosis, further investigations
and possibly improvements of the connec-
tor are necessary to evaluate the potential
benefits of this interesting technology.
Oliver Reuthebuch, MD
Mario Lachat, MD
Alexander Kadner, MD
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CH-8091 Zurich, Switzerland
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Horner syndrome
To the Editor:
I compliment Naimer and associates1 for
drawing attention to the important problem
of Horner syndrome after manipulation of
the subclavian artery in the neonate. As
Naimer and associates1 pointed out in their
report, there are remarkably few references
to this complication. Although Horner syn-
drome may seem to be a minor problem to
physicians caring for children with com-
plex congenital heart disease, its cosmetic
consequences are certainly not viewed
lightly by parents of affected children.
Horner syndrome not only has been de-
scribed after subclavian flap aortoplasty, as
in the report by Naimer and associates,1 but
also is seen regularly after a thoracotomy
approach to construction of either a modi-
fied or classic Blalock shunt. I believe that
this is one of the important advantages of
approaching construction of a modified
Blalock shunt through a median sternot-
omy. In our 1995 report,2 my colleagues
and I found no cases of Horner syndrome
among 52 patients who had a modified
Blalock shunt constructed through a ster-
notomy approach. We also found a signif-
icantly lower probability of shunt failure
with the sternotomy approach than with the
thoracotomy approach. I believe that the
sternotomy approach is technically easier
and less likely to result in distortion of the
hilar branches because the distal anastomo-
sis is placed more proximally on the branch
pulmonary artery. This also facilitates sub-
sequent takedown of the shunt. In contrast
to our experience with the sternotomy ap-
proach, we found that 2 of 16 patients who
underwent a thoracotomy approach as part
of first-stage preparation for a rapid two-
stage arterial switch had Horner syndrome
develop.2
I am in complete agreement with the
conclusion of Naimer and associates1 that
there are probably many unidentified cases
of Horner syndrome that occur after ma-
nipulation of the neonatal subclavian ar-
tery. Careful consideration should be given
to choosing surgical techniques and ap-
proaches that avoid manipulation of the
subclavian artery in the region of the sym-
pathetic pathway.
Richard A. Jonas, MD
Cardiovascular Surgeon-in-Chief
Children’s Hospital
300 Longwood Ave
Boston, MA 021153
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Impact of comorbidity on survival
after surgical resection in patients
with stage I non–small cell lung
cancer
To the Editor:
I read with interest the recent article by
Battafarano and associates1 on significantly
adverse impact of comorbidity on survival
of patients with resected stage I non–small
cell lung cancer. Although the vast major-
ity of patients with early stage (I and II)
disease are treated with surgery, a small
subset of these patients are not candidates
for surgery because of preexisting comor-
bidity. Such patients are treated with radio-
therapy alone.2-9 In this patient population
high-dose, standard fraction, or hyperfrac-
tionated radiotherapy is capable of achiev-
ing median survivals as long as 30 months
and 5-year survivals as great as 30%,7,8
with values going up to approximately 40
months and 40%, respectively, for T1 N0
cases.9
This patient population clearly repre-
sents a case of extremely negative selec-
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tion in which, as observed in their surgi-
cal counterparts, numerous cancer-
unrelated events seriously distort the
overall picture of the effectiveness of ra-
diotherapy. Indeed, when additional end
points such as cause-specific or disease-
free survivals are offered, the magnitude
of the difference between overall and
cause-specific survivals in these re-
ports2-6 have usually been between 15%
and 20%.2-6 It is therefore obvious that in
this patient population the use of cause-
specific or disease-free survival is man-
datory to correct for events that are not
cancer related. Similarly to surgical se-
ries, it is observed that intercurrent
deaths are directly correlated with in-
creasing age and preexisting comorbidity
(21%-43%).5-9
Although patients with early stage non–
small cell lung cancer treated with surgery
and those treated with radiotherapy cannot
be meaningfully compared, they share the
risk of cancer-unrelated death from serious
comorbidity. As we have seen from this
article,1 these risks could be identified and
stratified or grouped, which knowledge
could be used to optimally address the
treatment in this disease.
Branislav Jeremic, MD
Technical University Munich
Klinikum rechts der isar
Department of Radiotherapy
Munich, Germany
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